Arvinas Inc.
We are a clinical-stage biotechnology company dedicated to improving the lives of patients suffering from debilitating and life-threatening diseases. Through our PROteolysis TArgeting Chimera, or PROTAC, protein degradation platform, we are pioneering the development of a new class of therapeutics designed to harness the body s ow n natural protein disposal system to selectively and ef…
$6.97
-$0.19 (-2.65%)
EOD Oct 16, 2026
The business is unprofitable at the operating level (-45.13% margin). The thesis depends entirely on whether and when it reaches sustainable profitability.
Revenue declined 0.3% YoY. The question is whether this is cyclical or a structural shift.
At 29x earnings, the current multiple leaves limited room for execution misses or growth deceleration. Negative free cash flow of -$276M. The business is consuming cash, not generating it.
29.0x earnings. Not cheap, the quality is already reflected in the price. Upside from here requires either margin expansion or growth re-acceleration, not just continuation.
Price History
Valuation & Multiples
Based on TTM earnings · Diluted shares
Profitability & Returns
Revenue (TTM)
$317M
▼ -0.3% YoY
Net Income (TTM)
$9M
▲ +59.4% YoY
Op. Margin
-5.72%
▲ +49.9pp YoY
ROIC
-2.88%
▲ +13.6pp YoY
Cash Flow & Balance Sheet
FCF (TTM)
-$209M
▼ -5.6% YoY
Op. Cash Flow (TTM)
-$207M
▼ -5.6% YoY
Net Debt
-$560M
Net Cash Position
Cash & Equiv.
$568M
5Y CAGR: +58.9%
Continue Research
SourceComputed from the 10-Q filed 31 Jul 2026, covering the period ending 30 Jun 2026, as reported to the SEC. Data last refreshed 5 Aug 2026. How this is calculated.
Price from market data, last close as of 16 Oct 2026. Fiscal year ends Dec. Sector medians are approximate S&P 500 benchmarks and update periodically.
Is Arvinas (ARVN) overvalued?
At a P/E of 29.0, Arvinas (ARVN)'s valuation is best read against its own history, its peers, and the growth its price implies. A high multiple is not the same as overvalued: fast-growing, high-quality businesses can deserve a premium. See the general approach in how to tell if a stock is overvalued.
On quality, Arvinas scores 46/100 on Intrinsiqq's quality scorecard (a mixed business on these measures), weighing growth, margins, returns on capital, share count, and balance-sheet strength. All figures are computed from SEC filings; read the full methodology, or see how the market compares in our US profitability statistics. This is analysis, not investment advice.
Frequently asked
Is Arvinas a high-quality business?+
Arvinas scores 46 out of 100 on Intrinsiqq's quality score, a weighted blend of 7 metrics each scored 0 to 100, which makes it a mixed business on these measures. Recent fundamentals include a -5.7% operating margin and a -2.9% return on invested capital. The score weighs revenue and free-cash-flow growth, operating margins, return on invested capital, share-count change, and balance-sheet strength, all computed from SEC filings, not opinion. Because valuation only means something relative to quality, the full metric-by-metric breakdown is on the quality scorecard.
Is Arvinas a good stock to buy right now?+
That depends on valuation and quality together, not either alone. you should weigh ARVN's valuation and scores 46/100 on quality (mixed). A cheap price is only a bargain if the business is durable, and a premium can be justified by genuine quality, so the two questions, "is it cheap?" and "is it good?", only make sense side by side. Read the valuation against the quality scorecard, run the DCF on your own assumptions, and decide for yourself. This is analysis from SEC filings, not investment advice.
Related stocks: Pharmaceutical Preparations
Spot a number that looks wrong?
Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.